Methods of Normalizing Aberrant Glycolytic Metabolism in Cancer Cells
AssigneeThe Board of Trustees of the Leland Stanford Junior Unviersity
InventorsChirag Bihesh PATEL, Corinne G. Beinat, Edwin Chang, Sanjiv Sam Gambhir, Arutselvan Natarajan
Life of this patent
Estimating the term…
Abstract
Viability of cancer cells (e.g., glioblastoma cells) can be reduced by administering mannose to the cancer cells; and applying an alternating electric field with a frequency between 100 and 500 kHz to the cancer cells. Susceptibility to treatment with an alternating electric field can be determined by measuring uptake of a PKM2 probe (e.g., [18F]DASA) before and after treatment with an alternating electric field. Notably, experiments show that the combination of mannose and the alternating electric field produces a synergistic anti-glioblastoma result.
Claims19
A method of determining susceptibility of patient to treatment of cancer with alternating electric fields comprising:
- administering a PKM2 probe to a patient having cancer;
- measuring a first level of PKM2 uptake in cancer cells of the patient;
- exposing the cancer cells to treatment using alternating electric fields at a frequency between 100 and 500 kHz after measuring the first level;
- measuring a second level of PKM2 uptake in the cancer cells;
- and
- determining if the patient is susceptible to treatment using alternating electric fields based on whether the first level is higher than the second level by at least 5%.
A method of reducing a viability of cancer cells, comprising:
- administering a PKM2 probe to a patient having cancer;
- measuring a first level of PKM2 expression or uptake of the PKM2 probe in cancer cells from the patient;
- exposing the cancer cells to alternating electric fields at a frequency between 100 and 500 kHz for a first interval of time after measuring the first level;
- measuring a second level of PKM2 expression or uptake of the PKM2 probe in the cancer cells after the first interval of time;
- and
- continuing exposing the cancer cells to alternating electric fields if the first level is higher than the second level by at least 5%.
A method of determining susceptibility of patient to treatment of cancer using alternating electric fields, comprising:
- administering mannose labelled with an imaging probe to cells of patient having cancer;
- measuring a first level of uptake of the mannose labelled with an imaging probe in cancer cells from the patient;
- treating the cancer cells with alternating electric fields at a frequency between 100 and 500 kHz for a first interval of time after measuring the first level;
- measuring a second level of uptake of the mannose labelled with an imaging probe in the cancer cells after the first interval of time;
- and
- continuing treatment of the cancer cells using alternating electric fields if the first level is lower than the second level by at least 10%.
A method of reducing a viability of cancer cells, comprising administering mannose to cancer cells of a patient having cancer and then exposing the cancer cells to alternating electric fields at a frequency between 100 and 500 kHz.
A method of reducing a viability of cancer cells, comprising:
- administering a PKM2 probe to a patient having cancer;
- measuring a first level of PKM2 expression or uptake of the PKM2 probe in cancer cells from the patient;
- exposing the cancer cells to alternating electric fields at a frequency between 100 and 500 kHz for a first interval of time after measuring the first level;
- measuring a second level of PKM2 expression or uptake of the PKM2 probe in the cancer cells after the first interval of time;
- and
- administering a chemotherapeutic agent to the cancer cells if the first level is higher than the second level by at least 5%.
Dependencies are inferred from the claim text.